Search

everythinglearnresearchcommunity

for

Search:↓

Some multiple sclerosis treatments may trigger hair loss conditions like alopecia areata.

A comprehensive approach to educating patients and managing side effects is crucial for improving adherence to multiple sclerosis treatments and patient quality of life.

Teriflunomide effectively reduces relapses and disability in MS and has a manageable safety profile.

Hair thinning is a common but generally mild and reversible side effect of teriflunomide in multiple sclerosis patients.

Teriflunomide is effective and generally safe for treating relapsing multiple sclerosis, reducing relapse rates and disability progression.

Creators of YouTube 'bro-science' baldness videos are driven by a need to share and persuade, often emphasizing authenticity and community building, while navigating trust issues related to commercial ties.

Fat tissue cells are a promising option for healing various diseases, but more research is needed to ensure they are safe and effective.

Paternal drug exposure can harm fertility, pregnancy outcomes, and offspring health, with specific drugs linked to various reproductive issues.

Interferon beta treatment in MS patients can cause skin reactions and increased hair loss.

The document concludes that managing side effects of MS therapies is crucial for treatment success and patient adherence.

Taking vitamin D might improve life for MS patients and reduce skin side effects from alemtuzumab treatment.

New treatments for relapsing multiple sclerosis are more effective and convenient but have higher risks of serious side effects.

Daclizumab may cause psoriasis-like skin problems in multiple sclerosis patients.

Vacuum massage may improve skin elasticity and induce changes in skin cells, but evidence for treating burn scars is insufficient and more research is needed.

Dimethyl-fumarate may cause temporary hair loss.

Two patients developed complete hair loss after Alemtuzumab treatment for MS, with no regrowth after two years.

Teriflunomide is an effective and generally safe oral treatment for relapsing MS, reducing relapses and slowing disability progression.

Teriflunomide is an effective and safe first-line oral treatment for relapsing multiple sclerosis.

Teriflunomide effectively reduces relapse rates and disease progression in multiple sclerosis but is not safe for use during pregnancy.

A patient with multiple sclerosis developed skin reactions after Daclizumab treatment, requiring more data on the drug's effects.

The article suggests managing interferon beta therapy side effects in MS with dose adjustments, medications, and patient education.

Teriflunomide helps reduce multiple sclerosis symptoms and is safe for most patients.

Teriflunomide is effective and generally safe for treating relapsing-remitting multiple sclerosis.

Hyperbaric oxygen therapy shows promise for multiple sclerosis, but skepticism and funding issues limit tech use in clinics, and outdated single-drug cancer treatments may cause unnecessary side effects.

New findings suggest potential treatments for melanoma, hyperpigmentation, hair defects, and multiple sclerosis, and show skin microbiome changes don't cause atopic dermatitis.

Nail loss may be a side effect of the MS drug teriflunomide.

Teriflunomide is safe and tolerable for treating relapsing-remitting multiple sclerosis, with manageable side effects.

Janus kinase inhibitors are promising drugs for treating autoimmune and inflammatory diseases.

Some cells may slow melanoma growth, a protein could affect skin pigmentation, a gene-silencing method might treat hair defects, skin bacteria changes likely result from eczema, and a defensin protein could help treat multiple sclerosis.

Teriflunomide often causes mild to moderate hair thinning and loss in MS patients, which usually improves with or without treatment.